{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:42:26Z","timestamp":1789994546006,"version":"4.0.1"},"reference-count":14,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T00:00:00Z","timestamp":1731801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T00:00:00Z","timestamp":1731801600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Gemcitabine and docetaxel (GD) is a common chemotherapy regimen for metastatic soft tissue sarcoma (STS). The GeDDiS trial compared GD with doxorubicin in the first\u2010line setting, using gemcitabine 675\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      over a prolonged rate of 90 min\u2014reporting a 20% response rate and 5.4\u2010month median progression\u2010free survival (PFS). We aimed to examine the real\u2010world efficacy and toxicity of GD in our center, using a standardized dose of gemcitabine 900\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      over 30 min on Days 1 and 8 and intravenous docetaxel 75\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      over 60 min on Day 8 every 21 days.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted of patients with unresectable or metastatic STS receiving GD between July 2018 and October 2022. Data collected included patient and tumor characteristics, dose intensity, toxicity, response, PFS, and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty\u2010eight patients were included. Median follow\u2010up was 19 months (range 3\u201330). Line of treatment (\n                      <jats:italic>n<\/jats:italic>\n                      ) was first line (10), second line (13), \u2265 third line (15). The median number of cycles was 6. Response rate was 42%, including 5% with a complete response. At the time of data collection, 33 patients had disease progression and 24 patients had died. PFS (median, 6\u2010month rate) was 4.5 months and 44%. OS (median, 12\u2010month rate) was 15 months and 65%. Grade 3\/4 toxicity included anemia (21%), neutropenia (5%), thrombocytopenia (5%), and febrile neutropenia (3%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These data demonstrate the activity of gemcitabine using a standardized dose and rate with docetaxel comparable to other published data and favorable toxicity in a real\u2010life patient population despite altered gemcitabine dosing and a heavily pretreated patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ajco.14138","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:20:11Z","timestamp":1731889211000},"page":"305-310","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real\u2010World Outcomes of Patients Treated With Gemcitabine Using Standardized Dose and Rate and Docetaxel for Advanced Soft Tissue Sarcoma in an Australian Sarcoma Center"],"prefix":"10.1111","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9735-1320","authenticated-orcid":false,"given":"Isabella","family":"Wilson","sequence":"first","affiliation":[{"name":"Chris O'Brien Lifehouse  Sydney New South Wales Australia"},{"name":"Faculty of Medicine and Health The University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Strach","sequence":"additional","affiliation":[{"name":"Chris O'Brien Lifehouse  Sydney New South Wales Australia"},{"name":"Faculty of Medicine and Health The University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Bhadri","sequence":"additional","affiliation":[{"name":"Chris O'Brien Lifehouse  Sydney New South Wales Australia"},{"name":"Faculty of Medicine and Health The University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Harrison","sequence":"additional","affiliation":[{"name":"Chris O'Brien Lifehouse  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whiter","family":"Tang","sequence":"additional","affiliation":[{"name":"Chris O'Brien Lifehouse  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2653-1657","authenticated-orcid":false,"given":"Peter","family":"Grimison","sequence":"additional","affiliation":[{"name":"Chris O'Brien Lifehouse  Sydney New South Wales Australia"},{"name":"Faculty of Medicine and Health The University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,11,17]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Soft Tissue Sarcoma (Version 2.2023) National Comprehensive Cancer Network 2023 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/sarcoma.pdf."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.07.006"},{"key":"e_1_2_9_4_1","volume-title":"(Gemcitabine HCI) for Injection","author":"Gemzar","year":"1996"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.050"},{"key":"e_1_2_9_6_1","unstructured":"Soft Tissue Sarcoma Metastatic DOCEtaxel and Gemcitabine eviQ 2021 https:\/\/www.eviq.org.au\/medical\u2010oncology\/sarcoma\/soft\u2010tissue\u2010sarcoma\/1898\u2010soft\u2010tissue\u2010sarcoma\u2010metastatic\u2010docetaxel\u2010and."},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-014-0214-8"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S210117"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304369"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30622-8"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3781"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.02.024"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/RMHP.S442692"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2016.535"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21867"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.14138","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajco.14138","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.14138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T08:37:49Z","timestamp":1773477469000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.14138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,17]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1111\/ajco.14138"],"URL":"https:\/\/doi.org\/10.1111\/ajco.14138","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,17]]},"assertion":[{"value":"2024-02-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}